Atty Dkt No. PP01618.003

USSN: 09/728,423

PATENT

In the claims:

Please amend claims 1, 4-12, 14, 16-17 and 26-27 as follows:

- 1. (Amended) A method of eliciting an immune response against a hepatitis C virus (HCV) E2 or E1E2 antigen comprising the step of (a) administering to a subject a polynucleotide encoding an HCV E1E2 antigen or a full-length E2 antigen, wherein the E2 or E1E2 antigen encoded by the polynucleotide is not secreted when expressed in cells of the subject.
- 4. (Amended) The method of claims 1-3 or claim 7, wherein the polynucleotide encodes an E1E2 polypeptide.
- 5. (Amended) The method of claims 1-3 or claim 7, wherein the polynucleotide encodes a full-length E2 polypeptide.
- 6. (Amended) The method of claims 1-3 or claim 7, wherein the HCV antigen does not comprise a p7 polypeptide.
- 7. (Amended) The method of claim 1, wherein the HCV antigen encoded by the polynucleotide is selected from the group consisting of amino acids 384-746 of an HCV polyprotein; amino acids 384-749 of an HCV polyprotein; amino acids 192-746 of an HCV polyprotein, amino acids 192-809 of an HCV polyprotein; amino acids 192-749 of an HCV polyprotein; and amino acids 384-809 of an HCV polyprotein, wherein the amino acids are numbered relative to HCV-1.
 - 8. (Amended) The method of claims 1-3 or claim 7, wherein the polynucleotide is


Atty Dkt No. PP01618.003 USSN: 09/728,423 PATENT

in a plasmid.

9. (Amended) The method of claims 1-3 or claim 7, wherein the subject is infected with an HCV.

A3

- 10. (Amended) The method of claims 1-3 or claim 7, wherein the subject is not infected with an HCV.
- 11. (Amended) The method of claims 1-3 or claim 7, further comprising the step of administering cardiotoxin to the subject.
- 12. (Amended) The method of claims 1-3 or claim 7, wherein the polynucleotide is administered using a microparticle.
- 14. (Amended) The method of claims 1-3 or claim 7, wherein the subject is a mammal.
- 16. (Amended) The method of claims 1-3 or claim 7, wherein the polynucleotide is administered using a biolistic delivery device.
- 17. (Amended) The method of claims 1-3 or claim 7, wherein the polynucleotide is administered by a method selected from the group consisting of intramuscular, subcutaneous, intraperitoneal, intranasal, oral, and intradermal administration.



Atty Dkt No. PP01618.003 USSN: 09/728,423

PATENT

27. (Amended) The method of claims 1-3 or claim 7, further comprising administering to the subject a polypeptide encoded by the polynucleotide.

Attached hereto is a version showing changes made to the specification. Deletions are shown by strikethroughs and additions are underlined. Also attached hereto is a page titled "Version with markings to show changes made to claims" as well as a "currently pending claim set."